Affimed And BioNTech Immunotherapies Among Ones To Watch At AACR
Range Of New Modalities Put To Test
Affimed looks to build on the splash at last year’s American Association for Cancer Research meeting next month, while BioNTech aims to prove its immunotherapy capabilities with a CAR-T candidate.
You may also be interested in...
Under pressure to show Moderna can grow the company’s mRNA vaccines portfolio beyond COVID-19, CEO Stéphane Bancel has talked down his rivals in the field.
Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.